Literature DB >> 33053231

Irisin Correlates Positively With BMD in a Cohort of Older Adult Patients and Downregulates the Senescent Marker p21 in Osteoblasts.

Graziana Colaianni1, Mariella Errede2, Lorenzo Sanesi1, Angela Notarnicola2, Monica Celi3, Roberta Zerlotin1, Giuseppina Storlino1, Patrizia Pignataro2, Angela Oranger1, Vito Pesce2, Umberto Tarantino3, Biagio Moretti2, Maria Grano1.   

Abstract

Irisin is a myokine produced by skeletal muscle during exercise in both mice and humans. We previously showed that irisin treatment ameliorates immobility-induced osteoporosis and muscular atrophy in mice. Data in humans showed a positive association between irisin and bone mineral density (BMD) in athletes and a population of healthy children. However, the role of this myokine regarding the state of muscle and bone in the same population remained to be determined. For this purpose, 62 patients (age 68.71 ± 12.31 years) undergoing total hip or knee replacement were recruited. Our results showed that irisin serum levels negatively correlated with age (R = -0.515; p = .000018) and positively correlated with femoral BMD (R = 0.619; p = .001) and vertebral BMD (R = 0.201; p = .0001). Irisin was also positively associated with Fndc5 mRNA in muscle biopsies (R = 0.248; p = .016), as well as with Osteocalcin (Ocn) mRNA in bone biopsies (R = 0.708; p = .006). In skeletal muscle, FNDC5 positive fibers positively correlate with BMD of total femur (R = 0.765; p = .0014) and BMD of femoral neck (R = 0.575; p = .031), Interestingly, by analyzing patients divided by their T-score, we found lower irisin levels (p = .0011) in patients with osteopenia/osteoporosis (OP) compared to healthy controls matched for age and sex. By analyzing the senescence marker p21, we found a significant increase of its mRNA expression in the bone biopsies of OP patients compared to control ones. Therefore, we investigated in vitro whether rec-irisin had a direct effect on this senescence marker, showing that p21 mRNA expression was significantly downregulated in osteoblasts by the treatment with irisin. Overall, these results indicate that higher irisin levels are associated with a lower rate of age-related osteoporosis and that irisin could be effective in delaying the osteoblast aging process, suggesting a potential senolytic action of this myokine.
© 2020 American Society for Bone and Mineral Research (ASBMR). © 2020 American Society for Bone and Mineral Research (ASBMR).

Entities:  

Keywords:  BONE-MUSCLE INTERACTIONS; IRISIN; OSTEOPOROSIS; SARCOPENIA; SENESCENCE

Mesh:

Substances:

Year:  2020        PMID: 33053231     DOI: 10.1002/jbmr.4192

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  15 in total

Review 1.  The role of senolytics in osteoporosis and other skeletal pathologies.

Authors:  Madison L Doolittle; David G Monroe; Joshua N Farr; Sundeep Khosla
Journal:  Mech Ageing Dev       Date:  2021-09-06       Impact factor: 5.498

Review 2.  Role of the Myokine Irisin on Bone Homeostasis: Review of the Current Evidence.

Authors:  Amanda Kornel; Danja J Den Hartogh; Panagiota Klentrou; Evangelia Tsiani
Journal:  Int J Mol Sci       Date:  2021-08-24       Impact factor: 6.208

Review 3.  [Research progress on mechanism of myokines regulating bone tissue cells].

Authors:  Hongcheng Peng; Zhen Hua; Huilin Yang; Jianwei Wang
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2021-07-15

4.  In patients with anorexia nervosa, myokine levels are altered but are not associated with bone mineral density loss and bone turnover alteration.

Authors:  Laurent Maïmoun; Denis Mariano-Goulart; Helena Huguet; Eric Renard; Patrick Lefebvre; Marie-Christine Picot; Anne-Marie Dupuy; Jean-Paul Cristol; Philippe Courtet; Vincent Boudousq; Antoine Avignon; Sébastien Guillaume; Ariane Sultan
Journal:  Endocr Connect       Date:  2022-05-10       Impact factor: 3.221

Review 5.  FNDC5/Irisin System in Neuroinflammation and Neurodegenerative Diseases: Update and Novel Perspective.

Authors:  Patrizia Pignataro; Manuela Dicarlo; Roberta Zerlotin; Chiara Zecca; Maria Teresa Dell'Abate; Cinzia Buccoliero; Giancarlo Logroscino; Silvia Colucci; Maria Grano
Journal:  Int J Mol Sci       Date:  2021-02-05       Impact factor: 5.923

6.  The Effects of 8-Week Resistance and Endurance Trainings on Bone Strength Compared to Irisin Injection Protocol in Mice.

Authors:  Shirin Shahabi; Fahimeh Esfarjani; Jalil Reisi; Sedigheh Momenzadeh; Mohammad-Saeid Jami; Saeed Zamani
Journal:  Adv Biomed Res       Date:  2021-11-26

Review 7.  FNDC5/Irisin: Physiology and Pathophysiology.

Authors:  Rashid Waseem; Anas Shamsi; Taj Mohammad; Md Imtaiyaz Hassan; Syed Naqui Kazim; Anis Ahmad Chaudhary; Hassan Ahmed Rudayni; Mohammed Al-Zharani; Faizan Ahmad; Asimul Islam
Journal:  Molecules       Date:  2022-02-08       Impact factor: 4.411

8.  The Association of Serum Irisin with Bone Mineral Density and Turnover Markers in New-Onset Type 2 Diabetic Patients.

Authors:  Xiujing Wang; Tianxiao Hu; Yun Ruan; Jiaqi Yao; Huiling Shen; Yao Xu; Bojing Zheng; Zhengying Zhang; Jing Wang; Qingying Tan
Journal:  Int J Endocrinol       Date:  2022-02-28       Impact factor: 2.803

9.  BMP9 reduces age-related bone loss in mice by inhibiting osteoblast senescence through Smad1-Stat1-P21 axis.

Authors:  Jing-Zun Xu; Yan-Man Zhou; Lin-Lin Zhang; Xiao-Jing Chen; Yu-Ying Yang; Deng Zhang; Ke-Cheng Zhu; Xiao-Ke Kong; Li-Hao Sun; Bei Tao; Hong-Yan Zhao; Jian-Min Liu
Journal:  Cell Death Discov       Date:  2022-05-06

Review 10.  Irisin and Secondary Osteoporosis in Humans.

Authors:  Roberta Zerlotin; Angela Oranger; Patrizia Pignataro; Manuela Dicarlo; Filippo Maselli; Giorgio Mori; Silvia Concetta Colucci; Maria Grano; Graziana Colaianni
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.